Report Sections

See All Reports

Coronavirus Infections (722) Severe Acute Respiratory Syndrome (493) Infection (402) Pneumonia (331) Communicable Diseases (176) Respiratory Distress Syndrome, Adult (161) Acute Lung Injury (126) Respiratory Distress Syndrome, Newborn (126) (114) Syndrome (106) Virus Diseases (85) Pneumonia, Viral (73) Critical Illness (63) Depression (62) Anxiety Disorders (44) Disease (39) Stress Disorders, Post-Traumatic (34) Emergencies (31) Respiratory Tract Infections (31) Inflammation (30) Neoplasms (30) Cardiovascular Diseases (29) Stress Disorders, Traumatic (29) Wounds and Injuries (29) Lung Injury (27) Stress, Psychological (27) Mental Disorders (26) Diabetes Mellitus (25) Hypoxia (25) Depressive Disorder (24) Thrombosis (23) Hypertension (22) Respiratory Tract Diseases (22) Acute Kidney Injury (21) Lung Diseases (21) Disease Progression (18) Olfaction Disorders (18) Embolism (16) Influenza, Human (16) Stroke (16) Arthritis (15) Pulmonary Embolism (15) Respiration Disorders (15) Blood Coagulation Disorders (14) HIV Infections (14) Hemostatic Disorders (14) Thromboembolism (14) Burnout, Psychological (13) Chronic Disease (13) Fibrosis (13) Lung Diseases, Obstructive (13) Multiple Sclerosis (13) Sclerosis (13) Cognitive Dysfunction (12) Diabetes Mellitus, Type 2 (12) Lung Diseases, Interstitial (12) Myocardial Infarction (12) Pulmonary Disease, Chronic Obstructive (12) Pulmonary Fibrosis (12) Respiratory Aspiration (12) Arthritis, Rheumatoid (11) Autism Spectrum Disorder (11) Brain Injuries (11) Chronic Pain (11) Heart Diseases (11) Kidney Diseases (11) Substance-Related Disorders (11) Venous Thrombosis (11) Crohn Disease (10) Diabetes Mellitus, Type 1 (10) Heart Failure (10) Infarction (10) Lung Neoplasms (10) Autistic Disorder (9) Dyspnea (9) Myocarditis (9) Obesity (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Brain Injuries, Traumatic (8) Carcinoma (8) Colitis (8) Colitis, Ulcerative (8) Depression, Postpartum (8) Liver Diseases (8) Renal Insufficiency, Chronic (8) Respiratory Syncytial Virus Infections (8) Rheumatic Diseases (8) Ulcer (8) Vitamin D Deficiency (8) Coronary Artery Disease (7) Coronary Disease (7) Dementia (7) Feeding and Eating Disorders (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Kidney Failure, Chronic (7) Parkinson Disease (7) Problem Behavior (7) Pulmonary Valve Insufficiency (7) Venous Thromboembolism (7) Burnout, Professional (6) Collagen Diseases (6) Frailty (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Ischemia (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Musculoskeletal Pain (6) Overweight (6) Parasomnias (6) Pediatric Obesity (6) Psychotic Disorders (6) RNA Virus Infections (6) Sepsis (6) Shock (6) Spinal Cord Injuries (6) Acute Coronary Syndrome (5) Alcohol Drinking (5) Alcoholism (5) Autoimmune Diseases (5) Breast Neoplasms (5) Carcinoma, Non-Small-Cell Lung (5) Child Development Disorders, Pervasive (5) Convalescence (5) Coronaviridae Infections (5) Cystic Fibrosis (5) Delirium (5) Depressive Disorder, Major (5) Disease Susceptibility (5) Dyssomnias (5) Gastroparesis (5) Hypersensitivity (5) Leukemia (5) Lymphopenia (5) Multiple Organ Failure (5) Myocardial Ischemia (5) Neurologic Manifestations (5) Osteoarthritis (5) Prostatic Neoplasms (5) Renal Insufficiency (5) Alzheimer Disease (4) Asthma (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Brain Diseases (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Deglutition Disorders (4) Disseminated Intravascular Coagulation (4) Embolism and Thrombosis (4) Fibromyalgia (4) Head and Neck Neoplasms (4) Heart Arrest (4) Hemorrhage (4) Hypertension, Pulmonary (4) Liver Cirrhosis (4) Metabolic Syndrome (4) Migraine Disorders (4) Mycobacterium Infections (4) Neoplasm Metastasis (4) (4) Pancreatic Neoplasms (4) Postoperative Complications (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Apnea Syndromes (4) Sleep Initiation and Maintenance Disorders (4) Thrombophilia (4) Vascular Diseases (4) Weight Loss (4) Acquired Immunodeficiency Syndrome (3) Adenoviridae Infections (3) Appendicitis (3) Arrhythmias, Cardiac (3) Arthritis, Psoriatic (3) Asymptomatic Diseases (3) Bronchiectasis (3) Carcinoma, Renal Cell (3) Cardiomyopathies (3) Chilblains (3) Common Cold (3) Cross Infection (3) Dermatitis (3) Developmental Disabilities (3) Digestive System Diseases (3) Dysgeusia (3) Endometriosis (3) Fatigue (3) Fever (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Hemophilia A (3) Leukemia, Lymphoid (3) Macular Edema (3) Malnutrition (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Mucocutaneous Lymph Node Syndrome (3) (3) Nervous System Diseases (3) Neuroendocrine Tumors (3) Occupational Stress (3) Osteoarthritis, Knee (3) Ovarian Neoplasms (3) Panic Disorder (3) Paramyxoviridae Infections (3) Peripheral Arterial Disease (3) Polymyalgia Rheumatica (3) Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) Pregnancy Complications, Infectious (3) Premature Birth (3) Psychological Trauma (3) Pulmonary Edema (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Schizophrenia (3) Seizures (3) Sleep Apnea, Obstructive (3) Sleep Wake Disorders (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Tobacco Use Disorder (3) Triple Negative Breast Neoplasms (3) Ventricular Dysfunction (3) Ventricular Dysfunction, Left (3) Acute Disease (2) Ageusia (2) Agoraphobia (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Amyotrophic Lateral Sclerosis (2) Anemia, Sickle Cell (2) Angina Pectoris (2) Angioedema (2) Angioedemas, Hereditary (2) Anxiety, Separation (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrial Fibrillation (2) Bacterial Infections (2) Behcet Syndrome (2) Bipolar Disorder (2) Caliciviridae Infections (2) Clinical Deterioration (2) Cognition Disorders (2) Colorectal Neoplasms (2) Communicable Diseases, Emerging (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Congenital Abnormalities (2) Conjunctivitis (2) Dermatitis, Atopic (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Eczema (2) Emphysema (2) Endocrine System Diseases (2) Fatigue Syndrome, Chronic (2) Ganglion Cysts (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Gaucher Disease (2) Glioblastoma (2) Headache (2) Healthcare-Associated Pneumonia (2) Heart Defects, Congenital (2) Heart Failure, Systolic (2) Hematologic Diseases (2) Huntington Disease (2) Hyperglycemia (2) Hyperkinesis (2) Hyperphagia (2) Hypothermia (2) Hypoventilation (2) Idiopathic Pulmonary Fibrosis (2) Intervertebral Disc Degeneration (2) Intestinal Diseases (2) Ischemic Attack, Transient (2) Jaundice (2) Leukemia, Myeloid, Acute (2) Lymphoproliferative Disorders (2) Macular Degeneration (2) Mobility Limitation (2) Mood Disorders (2) Motor Neuron Disease (2) Multiple Myeloma (2) Multiple Sclerosis, Relapsing-Remitting (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myelodysplastic Syndromes (2) Myeloproliferative Disorders (2) Myositis (2) Necrosis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obesity, Morbid (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Pain, Postoperative (2) Peripheral Vascular Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Pneumocystis (2) Psoriasis (2) Purpura, Thrombocytopenic, Idiopathic (2) Rare Diseases (2) Recurrence (2) Respiratory Sounds (2) Sarcoidosis (2) Shock, Septic (2) Small Cell Lung Carcinoma (2) Spinal Diseases (2) Sprains and Strains (2) Suicidal Ideation (2) Suicide (2) Tachycardia (2) Thoracic Diseases (2) Thrombocytopenia (2) Toxemia (2) Trauma and Stressor Related Disorders (2) Tuberculosis (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Yellow Fever (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia, Aplastic (1) Angina, Stable (1) Anorexia (1) Anorexia Nervosa (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Back Pain (1) Bacteremia (1) Barotrauma (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bradycardia (1) Brain Concussion (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Bronchitis (1) Bronchitis, Chronic (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Calculi (1) Carcinoma, Hepatocellular (1) Carcinoma, Ovarian Epithelial (1) Carcinoma, Small Cell (1) Carcinoma, Squamous Cell (1) Cardiovascular Abnormalities (1) Cataract (1) Celiac Disease (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Clostridium Infections (1) (1) Colonic Diseases (1) Communication Disorders (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) (1) Coronary Artery (1) Coronary Stenosis (1) (1) Cough (1) Coxsackievirus Infections (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Calculus (1) Dental Plaque (1) Depressi (1) Depressive Disorder, Treatment-Resistant (1) DiGeorge Syndrome (1) Diabetic Nephropathies (1) Diabetic Neuropathies (1) Diphtheria (1) (1) Down Syndrome (1) Dyspareunia (1) Emergence Delirium (1) Encephalitis (1) Endocarditis (1) Endophthalmitis (1) Endotoxemia (1) Enuresis (1) Epilepsy (1) Esophageal and Gastric Varices (1) Esophagitis, Peptic (1) Eye Diseases (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Fatty Liver (1) (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Fistula (1) Food Hypersensitivity (1) Fractures, Closed (1) Fractures, Stress (1) Gait Disorders, Neurologic (1) Genetic Diseases, Inborn (1) Genetic Predisposition to Disease (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Gout (1) (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis (1) Hepatitis A (1) Hepatitis C (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hodgkin Disease (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperphosphatemia (1) Hyperplasia (1) Hypersensitivity, Immediate (1) Hypertension, Pregnancy-Induced (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Hypotension (1) Iatrogenic Disease (1) Infant, Newborn, Diseases (1) Infec (1) Infecti (1) Infertility, Female (1) Infertility, Male (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Keratosis (1) Keratosis, Actinic (1) Leishmaniasis (1) Leukemia, Lymphocytic, Chronic, B-Cell (1) Leukemia, Myeloid (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Low Back Pain (1) Lung (1) Lyme Disease (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Mantle-Cell (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth Diseases (1) Mouth, Edentulous (1) Movement Disorders (1) Mucositis (1) Multiple Chronic Conditions (1) Muscle Spasticity (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (1) Neuromyelitis Optica (1) Non-alcoholic Fatty Liver Disease (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis Media with Effusion (1) Overweig (1) Pain (1) Pain, Procedural (1) Pancreatitis (1) Paraproteinemias (1) Paresis (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Diseases (1) Peripheral Nervous System Diseases (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pleuropneumonia (1) (1) (1) Pneumonia, Bacterial (1) Pneumonia, V (1) Pre-Eclampsia (1) Pregnancy in Diabetics (1) Preleukemia (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein-Energy Malnutrition (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Radiculopathy (1) Rectal Neoplasms (1) Reperfusion Injury (1) (1) (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis, Pulmonary (1) Sarcopenia (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) (1) Scleroderma, Localized (1) Scleroderma, Systemic (1) Self-Injurious Behavior (1) Severe Acute Respiratory Syn (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Spinal Stenosis (1) Spondylarthritis (1) Spondylolisthesis (1) Status Epilepticus (1) Stillbirth (1) Stomatitis (1) Str (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Tachycardia, Sinus (1) Tachycardia, Ventricular (1) Temporomandibular Joint Disorders (1) Temporomandibular Joint Dy (1) Temporomandibular Joint Dysfunction Syndrome (1) Thalassemia (1) Thrombophlebitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Pulmonary (1) Ulce (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Ventricular Dysfunction, Right (1) Virus Dis (1) Von Willebrand Diseases (1) Vulvar Neoplasms (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D019966: Substance-Related Disorders

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (23)


Name (Synonyms) Correlation
drug397 BI 1569912 Wiki 0.30
drug3300 Surge capacity Wiki 0.30
drug3249 Standard therapy for AUD plus Chess-based cognitive treatment Wiki 0.30
Name (Synonyms) Correlation
drug2378 PEAR-008 Wiki 0.30
drug2049 Mindful Self-Compassion Wiki 0.30
drug2434 Patient Characteristics Wiki 0.30
drug3726 Woebot Substance Use Disorder Wiki 0.30
drug672 COVID-19 treatments Wiki 0.30
drug3197 Standard Dissemination Practice Wiki 0.30
drug3286 Suboxone Wiki 0.30
drug3605 Usual Care plus Customized Referrals Wiki 0.30
drug3244 Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment Wiki 0.30
drug3251 Standard therapy for TUD Wiki 0.30
drug1057 Differences in triage Wiki 0.30
drug2067 Mobile Enhanced Prevention Support Wiki 0.30
drug2620 PrEP Wiki 0.30
drug1642 Implementation Facilitation (IF) Wiki 0.30
drug670 COVID-19 test, polymerase chain reaction for SARS-CoV-2 Wiki 0.30
drug3377 Team Intervention Wiki 0.30
drug4076 reSET-O Wiki 0.30
drug3248 Standard therapy for AUD Wiki 0.30
drug399 BI 474121 Wiki 0.21
drug2505 Placebo Wiki 0.03

Correlated MeSH Terms (10)


Name (Synonyms) Correlation
D012749 Sexually Transmitted Diseases NIH 0.30
D015231 Sexually Transmitted Diseases, Bacterial NIH 0.30
D016739 Behavior, Addictive NIH 0.30
Name (Synonyms) Correlation
D006526 Hepatitis C NIH 0.30
D000437 Alcoholism NIH 0.27
D004194 Disease NIH 0.14
D040921 Stress Disorders, Traumatic NIH 0.06
D014947 Wounds and Injuries NIH 0.06
D004630 Emergencies NIH 0.05
D013313 Stress Disorders, Post-Traumatic NIH 0.05

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0030858 Addictive behavior HPO 0.30

Clinical Trials

Navigate: Correlations   HPO

There are 11 clinical trials


1 Opioid Use Disorder in the Emergency Department: Clinical Trials Network-0069

The purpose of this study is to evaluate the impact of (1) Implementation Facilitation (IF) on rates of provision of Emergency Department (ED)-initiated buprenorphine/naloxone (BUP) treatment with referral for ongoing medication-assisted treatment (MAT) and the (2) effectiveness of IF on patient engagement in formal addiction treatment at 30 days.

NCT03023930
Conditions
  1. Opioid Use Disorder
Interventions
  1. Other: Standard Dissemination Practice
  2. Other: Implementation Facilitation (IF)
MeSH:Disease Emergencies Substance-Related Disorders

Primary Outcomes

Description: The primary implementation outcome will be evaluated assessing the rate of ED-initiated BUP therapy with referral for ongoing MAT over the 12 month period.

Measure: Implementation (Considered the Primary Outcome)

Time: 12 months

Description: The primary effectiveness outcome is defined as the rates of patient engagement in formal addiction treatment on the 30th day post enrollment.

Measure: Effectiveness

Time: 30 Days Post Enrollment

Secondary Outcomes

Description: Fidelity will be measured using a critical action checklist relating to the provision of ED-initiated BUP with referral for ongoing MAT in eligible patients.

Measure: Implementation: Fidelity

Time: Baseline Period (Baseline)

Description: Fidelity will be measured using a critical action checklist relating to the provision of ED-initiated BUP with referral for ongoing MAT in eligible patients.

Measure: Implementation: Fidelity

Time: IF Evaluation Period (18 months)

Description: ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT

Measure: Implementation: ED provider Readiness and Preparedness Ruler Score

Time: Pre IF (Baseline)

Description: ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT

Measure: Implementation: ED provider Readiness and Preparedness Ruler Score

Time: Post IF (6 months)

Description: ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT

Measure: Implementation: ED provider Readiness and Preparedness Ruler Score

Time: post IF Evaluation Period (12 months)

Description: ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT

Measure: Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score

Time: Pre IF (Baseline)

Description: ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT

Measure: Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score

Time: Post IF (6 months)

Description: ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT

Measure: Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score

Time: Post IF Evaluation Period (12 months)

Description: Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community Readiness and Preparedness Ruler Score

Time: Pre IF (Baseline)

Description: Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community Readiness and Preparedness Ruler Score

Time: Post IF (6 months)

Description: Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community Readiness and Preparedness Ruler Score

Time: post IF Evaluation Period (12 months)

Description: Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community ORCA Score

Time: Pre IF (Baseline)

Description: Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community ORCA Score

Time: Post IF (6 months)

Description: Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community ORCA Score

Time: post IF Evaluation Period (12 months)

Description: Self-reported days of illicit opioid use (past 7 days) as measured by Time-Line Follow-Back methods at 30 days

Measure: Effectiveness: Opioid Use

Time: 30 days post enrollment

Description: Overdose event (past 30 days) captured by participant self-report, state medical examiner records, National Death Index and review of medical records

Measure: Effectiveness: Overdose Event

Time: 30 days post enrollment

Description: HIV risk taking behaviors (past 30 days) as measured by HIV Risk Taking Behavior Scale

Measure: Effectiveness: HIV Risk

Time: 30 days post enrollment

Description: All Healthcare Service Utilization Inpatient and Outpatient

Measure: Effectiveness: Healthcare Service Utilization

Time: 30 days post enrollment

Description: Rates of illicit opioid negative urines

Measure: Effectiveness: Illicit Opioid Urine Toxicology

Time: 30 days post enrollment
2 Mindful Self Compassion for Combat Deployed Veterans With Moral Injury and Co-occurring PTSD-SUD

Veterans with co-occurring Posttraumatic Stress Disorder and Substance Use Disorder (PTSD-SUD) experience more severe symptomatology and poorer response to existing treatments than Veterans with either disorder alone. Guilt is a common posttraumatic reaction and has been implicated as a risk factor for the development and maintenance of PTSD and substance use. Combat Veterans often report experiencing moral injury defined as perpetrating, failing to prevent, or witnessing acts that violate the values they live by in their civilian lives, which can lead to feelings of guilt and shame. Accordingly, reduction in guilt and increase in self-compassion may lead to improved quality of life for Veterans. This project will conduct a pilot study to evaluate changes in self-compassion, guilt, and PTSD-SUD symptom severity in a sample of Veterans after receiving 8 sessions of Mindful Self Compassion treatment (via a telehealth modality during COVID-19 pandemic). Findings will have significant impact on effective treatment options and lead to improvements in Veterans' quality of life and posttraumatic symptoms.

NCT03681288
Conditions
  1. Substance Use Disorder
  2. Post-tra
  3. Post-traumatic Stress Disorder
  4. Moral Injury
Interventions
  1. Behavioral: Mindful Self-Compassion
MeSH:Disease Substance-Related Disorders Wounds and Injuries Stress Disorders, Traumatic Stress Disorders, Post-Traumatic

Primary Outcomes

Description: The SCS is a 26-item self-report questionnaire in which respondents describe how they relate to themselves during times of distress. The SCS includes the 5 item Self-Kindness subscale (ranging from 5-25; higher scores reflect more self-kindness), the 5-item Self-Judgment subscale (ranging from 5-25; higher scores reflect more self-judgment), the 4-item Common Humanity subscale (ranging from 4-20; higher scores reflect higher levels of common humanity), the 4-item Isolation subscale (ranging from 4-20; higher scores indicate higher levels of isolation), the 4-item Mindfulness subscale (ranging from 4-20; higher scores reflect higher levels of mindfulness) and the 4-item Over-Identification subscale (ranging from 4-20). Responses are given on a 5-point scale from "1-Almost Never" to "5-Almost Always." Mean scores on the six subscales are then averaged to create an overall self-compassion score ranging from 26 to 130. Higher scores correspond to higher levels of self-compassion.

Measure: Self-Compassion Scale (SCS); Change from baseline in Self-Compassion at post-treatment (2 mo) and follow up (3mo)

Time: Baseline, 8-10 weeks, 12-14 weeks

Description: The TRGI is a 32-item validated self-report measure assessing traumatic guilt. The TRGI has three scales - Guilt Severity, Distress, and Guilt Cognitions. In all 32 items the answers are recorded on 5-point scale (ranging from 0 - not at all true to 4 - extremely true). Eight items are reverse-scored. We will use the TRGI as one of our eligibility criteria and to monitor changes in guilt and related cognitions over time.

Measure: Trauma-Related Guilt Inventory (TRGI); Change from baseline in trauma-related guilt at post-treatment (2 mo) and follow up (3mo)

Time: Baseline, 8-10 weeks, 12-14 weeks

Description: The ISS is a 30-item self-report measure assessing shame proneness scored on a 5-point Likert scale ranging from 0 = "never" to 4 = "almost always". The ISS yields sum scores for two subscales, self-esteem (6 items; range = 0-24 with higher scores reflecting higher levels of self-esteem) and internalized shame (24 items; range = 0-96 with higher scores reflecting higher levels of shame) and has been well-validated with research and clinical populations. The self-esteem items are interspersed to counteract a negative response set.

Measure: Internalized Shame Scale (ISS); Change from baseline in shame at post-treatment (2 mo) and follow up (3mo)

Time: Baseline, 8-10 weeks, 12-14 weeks

Secondary Outcomes

Description: The CAPS is a semi-structured interview used to assess PTSD diagnostic criteria and severity. Respondents select up to three of the most traumatic events they have experienced, and those events are used as the basis for assessing PTSD symptoms. The CAPS assesses each of the 20 items from the DSM-5 criteria B, C, D, and E. The assessor combines information about frequency and intensity of an item into a single severity rating (0=Absent; 1=Mild/subthreshold; 2=Moderate/threshold; 3=Severe/markedly elevated; 4=Extreme/incapacitating). CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms (range = 0-40). Similarly, CAPS-5 symptom cluster severity scores are calculated by summing the individual item severity scores for symptoms corresponding to a given DSM-5 cluster: Criterion B (items 1-5); Criterion C (items 6-7); Criterion D (items 8-14); and, Criterion E (items 15-20).

Measure: Clinician Administered PTSD Scale for DSM-5; Change from baseline in PTSD symptoms at post-treatment (2 mo) and follow up (3mo)

Time: Baseline, 8-10 weeks, 12-14 weeks

Description: The WHO-QOL BREF is a 26-item validated self-report measure that that assesses quality of life across four domains: physical (7 items, range 1-5), psychological (6 items, range 1-5), social relationships (3 items, range 1-5), and environment (8 items, range 1-5). The four domain scores denote an individual's perception of quality of life in each particular domain. The mean score of items within each domain is used to calculate the domain score. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life). There are also two items that are examined separately: question 1 asks about an individual's overall perception of quality of life on a scale of 1 - "very poor" to 5 - "very good". Question 2 asks about an individual's overall perception of their health on a scale of 1 - "very dissatisfied" to 5 - "very satisfied". The WHO-QOL-BREF has excellent internal validity and test-retest reliability.

Measure: Quality Of Life Enjoyment & Satisfaction Questionnaire (WHO-QOL-BREF); Change from baseline in quality of life at post-treatment (2 mo) and follow up (3mo)

Time: Baseline, 8-10 weeks, 12-14 weeks

Description: The Alcohol TLFB is a drinking assessment method that obtains estimates of daily drinking. The TLFB will be employed at all three assessment points to evaluate alcohol and other substance use during the 90 days preceding each interview. Using a calendar, people provide retrospective estimates of their daily drinking over a specified time period. The TLFB will be used at each follow-up to establish: percentage days heavy drinking, percent days abstinent, length of initial abstinence, length of use episodes, severity of relapse and current alcohol/drug use pattern. The Alcohol TLFB has been shown to have good psychometric characteristics with a variety of groups, and can generate variables that provide a wide range of information about an individual's use (e.g., pattern, variability, and magnitude of use).

Measure: Timeline Follow-back; Change from baseline in frequency of substance use at post-treatment (2 mo) and follow up (3mo)

Time: Baseline, 8-10 weeks, 12-14 weeks

Other Outcomes

Description: Beck Scale for Suicidal Ideation (BSSI): This scale is a 19-items instrument that evaluates the presence and intensity of suicidal thoughts in a week before evaluation (19). Each item is scored based on an ordinal scale from 0 to 2 and the total score is 0 to 38 with higher score indicating more risk for suicide.

Measure: Beck Scale for Suicidal Ideation; Change from baseline in suicidal risk at post-treatment (2 mo) and follow up (3mo)

Time: Baseline, 8-10 weeks, 12-14 weeks
3 Prevention Support for People Leaving Jail Study

This study will provide HIV prevention and related support services to men who have sex with men and transgender women who have substance use disorders and are either leaving jail or recently released from jail, living in a residential facility providing substance use services or supportive housing . The researchers will compare the utilization of HIV prevention and other support services between individuals who receive routine case management provided following enrollment to those who have access to GeoPassport, a global position service (GPS)-based mobile app, incentives, and peer mentor support.

NCT04036396
Conditions
  1. HIV Infections
  2. Sexually Transmitted Diseases, Bacterial
  3. Hepatitis C
  4. Substance Use Disorders
Interventions
  1. Behavioral: Mobile Enhanced Prevention Support
  2. Behavioral: Usual Care plus Customized Referrals
MeSH:Sexually Transmitted Diseases Sexually Transmitted Diseases, Bacterial Hepatitis C Substance-Related Disorders

Primary Outcomes

Description: Defined as the participant identifying and completing an appointment with a primary care provider who is willing and able to prescribe HIV pre-exposure prophylaxis. Provide documentation of the appointment.

Measure: Number of participants establishing a primary care provider who can prescribe PrEP (pre-exposure prophylaxis)

Time: 9 months

Description: Defined as the participant completing the screening process for PrEP with an eligible provider or PrEP navigator. Provide documentation of the appointment.

Measure: Number of participants obtaining screening for PrEP

Time: 9 months

Description: Defined as the participant obtaining a prescription for PrEP, providing documentation, reporting taking the medication

Measure: Number of participants who initiate PrEP regimen

Time: 9 months

Description: Defined as the participant self-reporting taking prescribed PrEP at least 4 days per week over the prior 30 days

Measure: Number of participants who demonstrate minimal adherence to PrEP

Time: 30 days

Description: The participant will provide documentation of filled PrEP prescriptions for 3 or more months

Measure: Number of participants who remain on PrEP for at least 3 months.

Time: 3 months

Description: Defined as the participant self-reporting having obtained HIV testing every 3 months over the 12 month follow-up period

Measure: Number of participants who undergo a HIV test every 3 months

Time: 9 months

Description: Defined by the participant self-reporting having obtained testing for these 3 bacterial sexually transmitted diseases (STDs) every 6 months over the 12 month follow-up period

Measure: Number of participants who undergo a test for gonorrhea, syphilis, and chlamydia every 6 months

Time: 9 months

Description: Defined by the participant self-reporting having obtained at least one test for Hepatitis C

Measure: Number of participants who undergo a test for hepatitis C

Time: 9 months

Description: Defined by the participant self-report of completing initial recommended SUD appointments within 3 months of jail release, consistent with each participant's recommended American Society of Addiction Medicine (ASAM) level of care

Measure: Number of participants obtaining treatment for substance use disorders (SUDs) in the community

Time: 3 months

Description: Defined by the participant self-reporting remaining engaged in treatment (i.e., continuing to attend meetings, counseling or other treatment activities) as defined by the recommended ASAM level of care in the 3 months prior to each follow-up interview.

Measure: Number of participants who remain engaged in treatment for substance use disorders (SUDs) in the community,

Time: 3 months

Secondary Outcomes

Description: Self-report of whether or not participants received follow-up care and treatment for HIV, STD, and hepatitis C infections diagnosed during study follow-up (n=300)

Measure: Number of participants in each arm receiving care and treatment for newly diagnosed HIV or STD infections.

Time: 9 months

Description: Measure the comparative effectiveness of each intervention arm on reducing recidivism (n=300), quantified as the number of respondents who are reincarcerated and the total number of reincarcerations per arm over the study period.

Measure: Number of participants in each arm experiencing recidivism

Time: 9 months

Description: Describe the temporal distribution of PrEP uptake and supportive social service utilization patterns of the participants in the MEPS intervention arm using data collected via the GeoPassport mobile app (n=150).

Measure: Temporal service utilization patterns of intervention arm participants

Time: 9 months

Description: Report the geographic distribution of PrEP uptake and supportive social service utilization patterns of the participants in the MEPS intervention arm using data collected via the GeoPassport mobile app (n=150).

Measure: Geographic service utilization patterns of intervention arm participants

Time: 9 months
4 Investigating Neurobiological Mechanisms of Chess as an Add-On Treatment Against Substance Use Disorder

Neurobiological and neuropsychological approaches to investigate the potential mechanism of action of chess as an add-on therapy (chess based - cognitive remediation treatment, CB-CRT) to reduce cognitive deficits in individuals with alcohol use disorder (AUD).

NCT04057534
Conditions
  1. Substance Use Disorders
Interventions
  1. Behavioral: Standard therapy for AUD plus Chess-based cognitive treatment
  2. Behavioral: Standard therapy for AUD
  3. Behavioral: Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment
  4. Behavioral: Standard therapy for TUD
MeSH:Substance-Related Disorders

Primary Outcomes

Description: fMRI cue-reactivity task (Vollstädt-Klein et al. 2010)

Measure: change in neural cue-reactivity

Time: 2 time points: before and after 6 weeks chess-based cognitive training

Description: fMRI sequential reinforcement-based task (Huys et al. 2012)

Measure: change in sequential reinforcement-based neural mechanisms

Time: 2 time points: before and after 6 weeks chess-based cognitive training

Description: fMRI stop-signal task (Whelan et al. 2012)

Measure: change in neural correlates of inhibition

Time: 2 time points: before and after 6 weeks chess-based cognitive training

Description: self-report

Measure: substance use (alcohol consumption and tabacco use)

Time: 3 months follow-up after the end of treatment

Description: fMRI spatial working memory task (Vollstädt-Klein et al. 2010)

Measure: change in neural working memory processes

Time: 2 time points: before and after 6 weeks chess-based cognitive training

Description: working memory capacity measured by letter-number sequencing task of the [Wechsler Memory Scale (Kent 2013)]; raw values will be transformed to IQ-like scales (mean 100, SD 15); the higher the value, the higher the working memory capacity

Measure: Change in working memory capacity

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: One Touch Stockings of Cambridge task from the Cambridge Automated Neuropsychological Test Automated Battery (Robbins et al. 1994)

Measure: Change in planning ability

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: Internal-External Set Shifting task from the Cambridge Automated Neuropsychological Test Automated Battery (Robbins et al. 1994)

Measure: Change in cognitive flexibility

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: impulsivity measured with BIS scale [Barratt impulsiveness scale (Patton et al. 1995)];range 15-60; total score will be used; high values represent high impulsivity

Measure: Change in impulsivity

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: [Iowa Gambling Task (Bechara et al. 1994)]

Measure: Change in decision-making

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: [Reversal learning task (Vanes et al. 2014)]

Measure: Change in mental flexibility

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: [d2 Test of Attention (Brickenkamp 2002)].

Measure: Change in attentional capacity

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Secondary Outcomes

Description: [measured with fMRI]

Measure: change in functional connectivity within the salience network (SN) and executive control network (ECN)

Time: 2 time points: before and after 6 weeks therapy and chess-based cognitive training
5 A Multi-Tiered Safety Net Following Naloxone Resuscitation From Opioid Overdose

The principal aim of this study is to determine whether a novel biopsychosocial intervention following opioid overdose (OD) affects 1) the frequency of secondary opioid OD events and 2) the proportion of individuals who remain engaged in treatment for opioid use disorder (OUD) or are in remission at 30 days and at 180 days post intervention. Remission is defined as engagement in daily medication-assisted therapy (MAT)-typically buprenorphine/naloxone (BUP) or methadone- and/or a recovery capital score of ≥ 27.5. The intervention principally involves connecting OUD-affected individuals with community resources, including BUP-, MAT-, and education-related services. To carry out the intervention, an addiction recovery coach and an appropriately trained health-educator paramedic (research assistant) will form a team and perform follow-up visits (electronically/remotely and/or by phone) after a participant has experienced at least 1 opioid OD requiring naloxone resuscitation. Our hypothesis is that the intervention will decrease subsequent OD events and increase the likelihood of remission. To evaluate this hypothesis, data will be collected from self-report and from EPIC, Yale New Haven Hospital's medical record system. The secondary aim is to determine whether the intervention affects 1) the frequency of positive-urine tests for opioids and 2) the frequency and proportion of subjects self-reporting opioid use. Our hypothesis is that our intervention will decrease both. Data from the entire cohort will be compared in aggregate with patients who were started on BUP in the ED over the same time period and with historic controls.

NCT04253782
Conditions
  1. Opioid-Use Disorder (OUD)
Interventions
  1. Other: Team Intervention
MeSH:Substance-Related Disorders

Primary Outcomes

Description: Frequency of positive urine tests at 30 days after intervention (data obtained via chart review)

Measure: Frequency of positive urine tests at 30 days (chart review)

Time: 30 days post intervention

Description: Frequency of positive urine tests at 180 days after intervention (data obtained via chart review)

Measure: Frequency of positive urine tests at 180 days (chart review)

Time: 180 days post intervention

Description: Frequency of positive urine tests at 30 days after intervention (data obtained via self-report)

Measure: Frequency of positive urine tests at 30 days (self-report)

Time: 30 days post intervention

Description: Frequency of positive urine tests at 180 days after intervention (data obtained via self-report)

Measure: Frequency of positive urine tests at 180 days (self-report)

Time: 180 days post intervention

Secondary Outcomes

Description: Percentage of positive urine tests at 30 days after intervention (data obtained via chart review)

Measure: Percentage of positive urine tests at 30 days (chart review)

Time: 30 days post intervention

Description: Percentage of positive urine tests at 180 days after intervention (data obtained via chart review)

Measure: Percentage of positive urine tests at 180 days (chart review)

Time: 180 days post intervention

Description: Percentage of positive urine tests at 30 days after intervention (data obtained via chart review)

Measure: Percentage of positive urine tests at 30 days (self-report)

Time: 30 days post intervention

Description: Percentage of positive urine tests at 180 days after intervention (data obtained via self-report)

Measure: Percentage of positive urine tests at 180 days (self-report)

Time: 180 days post intervention
6 Quality of Life and Addiction Among Hospital Night Workers - Descriptive Study of APHP Workers in Paris

The current context of the Covid-19 health crisis leads to an over-solicitation of health systems, with hospital staff in the front line. These personnel are undergoing high levels of stress, an alteration of their life rhythm, but also of their health status and quality of life at work. In addition, night work, through the disruption of circadian rhythms, has consequences on physical and mental health. The more frequent worsening of the condition of certain patients at night increases the burden and responsibilities of night staff. Increasing the use of psychoactive substances (SPAs) can become a solution for managing stress, work rhythms, sleep disorders and their consequences. This self-medication behaviour is not without risks, neither for staff nor for patients. The ALADDIN study is a project made up of 2 waves of questionnaires - one during and the other after the Covid "hospital" crisis - filled in by the hospital night staff of AP-HP. This project will assess the impact of the Covid-19 epidemic on the quality of work life, mental health disorders, post-traumatic stress and substance use of hospital night staff. The main objectives of this study is to evaluate the prevalence of psychoactive substance consumption among the night shift healthcare workers of the AP-HP and to describe the participants' quality of working life. Methods The study is prospective study using an online self-completed questionnaire. The questionnaire was elaborated on the basis of the validated scales ASSIST (Alcohol, Smoking, and Substance Involvement Screening Test), AUDIT-C (Alcohol Use Disorder Test, shortened version) and HAD (for anxiety and depression) and on qualitative interviews conducted among care staff working the night shift. The questionnaire will be completed at t0 (baseline) and 18 months after. This study will provide data on the consumption psychoactive substances by night hospital workers adn their quality of working life. It will also allow us to compare their consumption with the general population, and to describe the risk factors influencing the consumption.

NCT04291534
Conditions
  1. Health Services Resear
  2. Health Services Research
  3. Quality of Life
  4. Addiction
  5. Substance-Related Disorders
  6. Health Personnel
MeSH:Substance-Related Disorders Behavior, Addictive
HPO:Addictive behavior

Primary Outcomes

Description: Prevalence in APHP health workers of psychoactive substance consumption during the Covid 19 outbreak

Measure: Substance use prevalence

Time: at T0 month : baseline

Description: Evaluation of the quality of working life during the Covid 19 outbreak using a validated scale

Measure: Quality of working life scale

Time: at T0 month : baseline

Secondary Outcomes

Description: Identify the preferences for intervention to improve the quality of life or change the addictive risk of night hospital staff at the APHP. Preferences for intervention methods and ranking of the least preferred.

Measure: Intervention preference

Time: at T0 month

Description: Describe the risk factors associated with the consumption of psychoactive substances (PAS). Logistic or fish linear regression depending on the type of variable taken into account.

Measure: Psychoactive substance consumption and associated factors

Time: at T0 month

Description: Evaluate the impact of substance use on quality of life at work Principal component analysis and classification to see if there are consumer groups for the night and / or day population. Method for taking into account missing, unused or invalid data

Measure: Impact of substance consumption on quality of life at work

Time: at T0 month

Description: Describe the risk factors associated with tobacco use among night hospital workers,

Measure: Risk factors associated with tobacco use

Time: at T0 month

Description: Evaluate the impact of sleep quality on the quality of working life and perceived health of night staff

Measure: Impact of sleep quality on quality of working life and perceived health

Time: at T0 month

Description: Describe the links between QWL and sleep, anxiety, depressive syndromes, and workplace upheaval.

Measure: Impact of anxiety and depressive symptoms on sleep and QWL.

Time: at T0 month

Description: Describe the links between anxiety/depressive syndromes and workplace disruption, sleep, and the Covid epidemic.

Measure: Impact of sleep and workplace upheaval on anxiety and depressives symptoms

Time: at T month

Description: Comparison between the baseline score and prevalences and the score and prevalences 18 months after

Measure: Modification of quality of working life score and psychoactive substances consumption prevalences

Time: T18 months

Description: Analysis of the relation between declared change and evolution of the quality of life score

Measure: Comparison of modification of quality of life score and declared quality of life modification after 18 month

Time: T18 months
7 Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment - EPILOGUE

The current containment linked to COVID-19 will have consequences for people suffering from addiction and there is a risk of overdoses when the containment ends. So the investigators hypothesize that this health crisis is an opportunity to develop risk reduction and access to care for vulnerable people who lives with an addiction. The main objective of this study is to describe the changes in the psychoactive substances consumption during the containment in people suffering from addiction. The secondary objectives are to describe the evolution at 1 month from the end of the containment of problematic consumption and the level of access to care of these users

NCT04343339
Conditions
  1. Addiction, Substance
  2. COVID-19
MeSH:Substance-Related Disorders Behavior, Addictive
HPO:Addictive behavior

Primary Outcomes

Description: measurement of the difference in drugs consumption caused by containment (delta)

Measure: Evolution of consumption

Time: 1 day

Description: measurement of the difference in drugs consumption caused by containment (delta)

Measure: Evolution of consumption

Time: 1 month after confinmant

Secondary Outcomes

Description: number of drug users referred to care (%)

Measure: health care access

Time: 1 day

Description: number of drug users referred to care (%)

Measure: health care access

Time: 1 month after confinmant
8 Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology

This study seeks to gather data and insight on epidemiologic trends of loneliness and other behaviors in the wake of the CDC recommended "social distancing" during the COVID-19 pandemic. The objective of this study is to use a cross-sectional survey to assess the impact of COVID-19's associated recommendations (social distancing, self-isolation, and self-quarantine) on loneliness and psychosocial symptomatology (depression, anxiety, substance abuse) on young adults (18-35 years old).

NCT04440098
Conditions
  1. Loneliness
  2. Depression
  3. Anxiety
  4. Alcohol Abuse
  5. Drug Abuse
MeSH:Alcoholism Substance-Related Disorders

Primary Outcomes

Description: University of California Los Angeles ( UCLA) Loneliness Scale is a 20-item self-report questionnaire that evaluates subjective feelings of loneliness and social isolation. Participants rate items on a 4-point Likert scale ranging from 1 (never) to 4 (often).Items are summed to create a score that can range from 20-80, higher scores being indicative of greater loneliness.

Measure: Loneliness as evaluated by the UCLA loneliness scale

Time: Day 1

Description: Alcohol Use Disorder Identification Test (AUDIT) is a 10-item self-reported questionnaire used to identify individuals whose alcohol consumption could be hazardous for their health. Participants rate items in a 5-point Likert scale, indicating amount (0 to 10 drinks or more), frequency (never to daily or almost daily), and indication of problems caused by alcohol (yes or no). Items were summed up to create a score that can range from 0 to 50. A score of 1 to 7 indicates low risk consumption, whereas a score of 8-15 suggests risky or hazardous drinking, a score of more than 15 is likely to indicate high-risk drinking and alcohol dependence.

Measure: Alcohol Use as evaluated by the AUDIT

Time: Day 1

Description: The Drug Abuse Screening Test (DAST-10) is a 10-item self-reported screening test that provides a quantitative index of the degree of consequences related to drug abuse. Participants rate items yes or no, positive responses corresponding to 1 point. Items are summed up to create a score that can range from 0-10. A score of 1-2 represents risky behaviors related to drugs, 3-5 represents moderate problems, 6-8 represents substantial problems, and 9-10 represents severe problems.

Measure: Drug Use as evaluated by the DAST-10

Time: Day 1

Description: The General Anxiety Disorder Scale (GAD- 7) is a 7- item self-reported screening tool that assess presence and severity of Generalized Anxiety Disorder. Participants rated frequency of problems in a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). Items are summed up to create a score with scores of 5, 10, and 15 being the cut-off points for mild, moderate and severe anxiety, respectively.

Measure: Anxiety as evaluated by GAD-7

Time: Day 1

Description: The Center for Epidemiologic Studies Depression scale (CES-D-10) is a 10-item self-reported measure that assesses the frequency of symptoms of depression. Participants rate frequency of symptoms in a 4-point Likert scale from 0 (rare or none of the time) to 3 (most or almost all the time). Items are summed up to create a score that ranges from 0 to 30, with higher scores representing greater depressive symptoms. A score of 16 or more represents clinical depression.

Measure: Depression as assessed by CES-D-10

Time: Day 1
9 Woebot for Substance Use Disorders During COVID-19

The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.

NCT04460027
Conditions
  1. Substance Use Disorders
  2. Alcohol Use Disorder
Interventions
  1. Other: Woebot Substance Use Disorder
MeSH:Disease Alcoholism Substance-Related Disorders

Primary Outcomes

Measure: Change of number of days drinking

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Measure: Change of number of days drug use

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Secondary Outcomes

Measure: Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5 (AUDADIS-V)

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Measure: Short Inventory of Problems - Alcohol and Drugs (SIP-AD)

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Measure: Drug Abuse Screening Test (DAST-10)

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Measure: Brief Situational Confidence Questionnaire (BSCQ)

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Measure: Craving rating

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Description: Range from 0-100 (no pain to worst pain imaginable)

Measure: Pain rating

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Description: Total score between 0-27, higher scores indicate greater levels of depression

Measure: Patient Health Questionnaire-9 (PHQ-9)

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Description: Total score between 0-21, higher scores indicate greater levels of anxiety

Measure: General Anxiety Disorder-7 (GAD-7)

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Measure: CAIR Pandemic Impact Questionnaire (CAIR-PIQ)

Time: Difference between baseline and post-treatment (8 weeks from baseline)

Description: Range from 8 to 32, with higher values indicating higher satisfaction

Measure: Client Satisfaction Questionnaire (CSQ)

Time: Post-treatment (8 weeks from baseline)

Measure: Usage Rating Profile Intervention (URPI)

Time: Post-treatment (8 weeks from baseline)
10 Providing Comprehensive Harm Reduction Via Telemedicine for PWID Using Syringe Services Programs: a Feasibility Study

The purpose of this study is to provide medication for opioid use disorder (MOUD) with buprenorphine and naloxone, or bup/nx, and pre-exposure prophylaxis (PrEP) for HIV prevention for persons who inject opioids accessing syringe services programs (SSPs), as part of a comprehensive harm reduction program, and assess the acceptability and feasibility of using telemedicine to implement the program. The initial visit will be conducted in person or remotely via telemedicine given COVID-19 protocols at the SSP sites in Charlotte and Wilmington, North Carolina (NC); follow-up visits will be conducted via telemedicine.

NCT04521920
Conditions
  1. Opioid Use
  2. Opioid-use Disorder
  3. Risk Reduction
  4. Hiv
Interventions
  1. Drug: Suboxone
  2. Drug: PrEP
MeSH:Substance-Related Disorders

Primary Outcomes

Description: Defined as self-reported opioid use on ≤4 days in the past month and/or 2 or more consecutive negative urine tests.

Measure: Proportion who demonstrate no or minimal opioid use.

Time: 3 months

Description: Defined as self-reported opioid use on ≤4 days in the past month and/or 2 or more consecutive negative urine tests.

Measure: Proportion who demonstrate no or minimal opioid use.

Time: 6 months

Description: Measured via negative HIV test.

Measure: Proportion who remain HIV negative.

Time: 3 months

Description: Measured via negative HIV test.

Measure: Proportion who remain HIV negative.

Time: 6 months

Description: Defined as the proportion who remain on treatment (MOUD or PrEP).

Measure: Persistence in care

Time: 3 months

Description: Defined as the proportion who remain on treatment (MOUD or PrEP).

Measure: Persistence in care

Time: 6 months

Description: Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant (qualitative method)

Measure: Ease/difficulty of visiting a SSP to meet with a provider via telemedicine

Time: 1 month

Description: Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant over time (qualitative method)

Measure: Ease/difficulty of visiting a SSP to meet with a provider via telemedicine

Time: 6 month

Description: Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant (qualitative method)

Measure: Ease/difficulty of accessing the telemedicine video platform

Time: 1 month

Description: Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant (qualitative method)

Measure: Perceptions of medical care quality via a telemedicine video platform

Time: 6 month

Description: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant (qualitative method)

Measure: Participant satisfaction with the program

Time: 1 month

Description: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method)

Measure: Participant satisfaction with the program

Time: 6 month

Description: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant (qualitative method)

Measure: Participant perceived usefulness of the program

Time: 1 month

Description: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method)

Measure: Participant perceived usefulness of the program

Time: 6 month

Description: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method)

Measure: Motivators and barriers affecting program persistence

Time: 6 month

Description: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method)

Measure: Motivators and barriers affecting medication adherence and persistence

Time: 6 month
11 A Randomized, Controlled, Open-Label, Decentralized Study, to Evaluate Patient Engagement With PEAR-008, a Game-Based Digital Therapeutic for the Treatment of Opioid Use Disorder

The purpose of this study is to evaluate how patients use and engage with a game-based mobile application that is designed to treat opioid use disorder.

NCT04542642
Conditions
  1. Opioid-use Disorder
Interventions
  1. Device: reSET-O
  2. Device: PEAR-008
MeSH:Substance-Related Disorders

Primary Outcomes

Description: Evaluate the number of active sessions per week between PEAR-008 and reSET-O

Measure: Evaluate Participant Engagement Data

Time: From Week 1 to Week 8 (End of Treatment)

Secondary Outcomes

Description: Evaluate if PEAR-008 increases retention in treatment compared to reSET-O by comparing drop-out rates

Measure: Evaluate Treatment Retention Based on Drop-Out Rates

Time: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 (End of Treatment), Week 12 (Follow-up)

Description: Evaluate if PEAR-008 increases abstinence compared to reSET-O, as measured by saliva drug screens, urine drug screens and self-reporting

Measure: Evaluate Illicit Drug Abstinence

Time: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 (End of Treatment), Week 12 (Follow-up)

Description: Evaluate participants' digital therapeutic use patterns based on usage data collected, comparing PEAR-008 to reSET-O

Measure: Evaluate Digital Therapeutic Use Patterns Based on Usage Data

Time: From Week 1 to Week 8 (End of Treatment)

Description: Assess the effect of PEAR-008 and reSET-O on depressive symptoms using the eight-item Patient Health Questionnaire (PHQ-8) scores from Baseline to End of Treatment and Follow-up. The PHQ's total score ranges from 0 (not clinically significant) to 24 (clinically significant)

Measure: Assess Effect on Depressive Symptoms

Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)

Description: Assess the effect of PEAR-008 and reSET-O on anxiety symptoms using the Generalized Anxiety Disorder-7's (GAD-7) scores from Baseline to End of Treatment and Follow-up. The GAD-7's total score ranges from 0 (not clinically significant) to 21 (clinically significant)

Measure: Assess Effect on Anxiety Symptoms

Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)

Description: Assess the effect of PEAR-008 and reSET-O on recovery capital using the ten-item Brief Assessment of Recovery Capital (BARC-10) scores from Baseline to End of Treatment and Follow-up. The BARC-10's total score ranges from 10 to 60

Measure: Assess Effect on Recovery Capital

Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)

Description: Summarize participant satisfaction surveys and evaluate if PEAR-008 increases participant satisfaction in treatment compared to reSET-O through descriptive statistics

Measure: Describe Participant Satisfaction Surveys

Time: Baseline, Week 4, Week 8 (End of Treatment)

Description: Summarize participant satisfaction interviews and evaluate if PEAR-008 increases participant satisfaction in treatment compared to reSET-O through descriptive statistics

Measure: Describe Participant Satisfaction Interviews

Time: Week 12 (Follow-up)

Description: Assess the impact of the COVID-19 pandemic on participants using the five-item Council on American-Islamic Relations (CAIR) Pandemic Impact Questionnaire (C-PIQ) scores from Baseline to End of Treatment and Follow-up. The C-PIQ's total score ranges from 0 to 20

Measure: Assess Coronavirus Disease (COVID-19) Impact

Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)

Description: Assess the effect of the COVID-19 pandemic on depressive symptoms using the COPE: Coronavirus Perinatal Experiences - Impact Survey (COPE-IS) (MODIFIED) scores from Baseline to End of Treatment and Follow-up. Participants will be asked how they are coping with stress during COVID-19 from a list of responses. There is no scoring for this measure

Measure: Assess Coronavirus Disease (COVID-19) Impact on Stress

Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)

Other Outcomes

Description: Evaluate the correlation between engagement (daily and weekly participant use patterns of PEAR-008 and reSET-O) and treatment outcomes (abstinence and retention in treatment)

Measure: Evaluate Engagement and Efficacy Relationship

Time: From Week 1 to Week 8 (End of Treatment), Week 12 (Follow-up)

Description: Assess the effect of PEAR-008 and reSET-O on changes in skill acquisition using the Cognitive-Behavioral Therapy Skills Questionnaire (CBTSQ) from Baseline to End of Treatment. The CBTSQ measures two factors: Behavioral Activation (BA) and Cognitive Restructuring (CR). BA factor scores range from 0 to 35, and higher scores indicate greater use of BA skills. CR factor scores range from 0 to 45, and higher scores indicate greater use of CR skills

Measure: Change in Skill Acquisition

Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)

Description: Assess the effect of PEAR-008 and reSET-O on medication adherence rates using findings from saliva drug screens and urine drug screens

Measure: Medication Adherence Rates

Time: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 (End of Treatment), Week 12 (Follow-up)

HPO Nodes


HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,180 reports on interventions/drugs

MeSH

691 reports on MeSH terms

HPO

263 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook